Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TScan Therapeutics (TCRX) Return on Equity (2021 - 2025)

TScan Therapeutics (TCRX) has disclosed Return on Equity for 5 consecutive years, with 0.43% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Equity rose 11.0% to 0.43% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.43%, a 11.0% increase, with the full-year FY2025 number at 0.71%, down 7.0% from a year prior.
  • Return on Equity was 0.43% for Q4 2025 at TScan Therapeutics, roughly flat from 0.43% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.61% in Q2 2021 to a low of 0.82% in Q1 2023.
  • A 5-year average of 0.47% and a median of 0.51% in 2025 define the central range for Return on Equity.
  • Biggest YoY gain for Return on Equity was 25bps in 2022; the steepest drop was -105bps in 2022.
  • TScan Therapeutics' Return on Equity stood at 0.29% in 2021, then plummeted by -110bps to 0.61% in 2022, then grew by 9bps to 0.56% in 2023, then grew by 4bps to 0.54% in 2024, then rose by 21bps to 0.43% in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Return on Equity are 0.43% (Q4 2025), 0.43% (Q3 2025), and 0.51% (Q2 2025).